Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesNephrologyCigna Tolvaptan (Jynarque) Prior Auth Update | Ope…
    Ask Trek AI about this page
    ModifiedCignaPolicy IP0287

    Tolvaptan (Jynarque)

    Customize your policy alerts

    Sign up for Cigna Policy IP0287 alerts

    Get alerted when Policy IP0287 changes without checking for updates manually.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    Defines Cigna's prior authorization and medical necessity criteria for tolvaptan (Jynarque and generic) for treatment of autosomal dominant polycystic kidney disease (ADPKD) in adults; applies to Cigna-administered health benefit plans. Providers must follow the policy when requesting coverage.

    Policy Summary
    PayerCigna
    PolicyTolvaptan (Jynarque)
    Policy CodePolicy IP0287
    Change TypeMaterial revision — clarified baseline eGFR and added renal replacement therapy prohibition
    Effective DateAug 1, 2026
    Last ReviewAug 1, 2026
    Next Review DateN/A
    Key ActionObtain prior authorization and document baseline eGFR ≥ 25 mL/min/1.73 m2 and that the patient is not on dialysis or has had a transplant.
    SourceLink
    POLICY UPDATE CHANGES

    The requirement regarding kidney function was updated to require a baseline estimated glomerular filtration rate (eGFR) ≥ 25 mL/min/1.73 m2 rather than exclusion of Stage 5 CKD.

    Examples of rapidly declining renal function were added, including eGFR decline ≥ 3.0 mL/min/1.73 m2 and Mayo Classification 1C, 1D, or 1E.

    Policy name updated and Jynarque tablets are now available as a generic product; preferred product table for employer plans specifies trial of generic before brand under specified circumstances.

    Added requirement that a patient on tolvaptan therapy cannot be on renal replacement therapy and defined renal replacement therapy as dialysis or transplantation.

    ≥25

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    required baseline eGFR for approval
    ≥3.0rapid progression example eGFR decline
    1C–1EMayo classifications
    1 yrinitial approval duration
    REMSREMS
    genericproduct availability change

    Coverage Criteria for Tolvaptan (Jynarque and Generic)

    FDA-Approved Indication (Initial Therapy)

    Approve for 1 year if the patient meets ALL of the following (A–F):

    FDA-Approved Indication Criteria: A) Patient is >= 18 years of age; AND B) According to the prescriber, the patient has rapidly progressing autosomal dominant polycystic kidney disease (examples include historical eGFR decline >= 3.0 mL/min/1.73 m2 or Mayo Classification 1C, 1D, or 1E); AND C) At baseline, the patient has an estimated glomerular filtration rate (eGFR) >= 25 mL/min/1.73 m2; AND D) Patient is not on renal replacement therapy (defined as dialysis or kidney transplantation); AND E) The medication is prescribed by or in consultation with a nephrologist; AND F) Preferred product criteria is met for the product(s).

    Initial approval duration = 1 year

    Autosomal Dominant Polycystic Kidney Disease

    Covered when ALL of the following are met

    ADPKD baseline and therapy exclusions

    • Baseline kidney function: Baseline estimated glomerular filtration rate (eGFR) is >= 25 mL/min/1.73 m2 prior to any tolvaptan treatment.eGFR >= 25 mL/min/1.73 m2

      Baseline defined as prior to treatment with any tolvaptan product.

    • Not on renal replacement therapy: Patient is not on renal replacement therapy (no dialysis or kidney transplantation).

      Renal replacement therapy defined as dialysis or transplantation.

    Use of tolvaptan products for indications other than the FDA‑approved treatment of autosomal dominant polycystic kidney disease (ADPKD) is considered not medically necessary under this policy. Examples include use for hyponatremia (where an alternative tolvaptan product, Samsca, is the indicated therapy) and concomitant use with Samsca, which is not recommended.

    Patients who are receiving renal replacement therapy are excluded from tolvaptan therapy under this policy. Renal replacement therapy is defined as dialysis or kidney transplantation; requests for tolvaptan for patients on dialysis or after renal transplantation do not meet the coverage criteria.

    Tolvaptan products prescribed for non‑ADPKD indications are considered not medically necessary. For example, clinically significant hyponatremia should be treated with the tolvaptan product indicated for that condition (Samsca) rather than using tolvaptan intended for ADPKD, and concomitant use of different tolvaptan products is not recommended.

    Key Clinical Thresholds and Coding-related Metrics

    inv-06: Baseline eGFR
    Baseline eGFR requirementBaseline estimated glomerular filtration rate (eGFR) ≥ 25 mL/min/1.73 m2
    When measuredMeasured at baseline prior to treatment with any tolvaptan product
    Approval implicationRequired for approval under the FDA‑approved ADPKD indication (initial approval = 1 year)
    inv-07: Rapid progression eGFR decline example
    Example rapid eGFR declineHistorical eGFR decline ≥ 3.0 mL/min/1.73 m2 (per year or over documented period)
    Guideline basisListed as an example of rapid progression in consensus and KDIGO guidance

    Prior Authorization, Documentation, and Provider Requirements

    Prior Authorization

    Prior authorization required; approvals for 1 year and specialist involvement

    Prior authorization is required for benefit coverage of tolvaptan. All approvals are provided for the duration noted (initial approval = 1 year) and require the medication to be prescribed by or in consultation with a physician who specializes in the condition being treated (nephrologist).

    • Initial approval duration = 1 year.
    • Must be prescribed by or in consultation with a nephrologist.
    Prior Authorization

    Prior authorization requires baseline eGFR and absence of renal replacement therapy

    Prior authorization is required for tolvaptan products (Jynarque and generic) with criteria that include a documented baseline estimated glomerular filtration rate (eGFR) and that the patient is not on renal replacement therapy (dialysis or kidney transplantation).

    • Baseline eGFR requirement: ≥ 25 mL/min/1.73 m2 (baseline defined as prior to treatment with any tolvaptan product).

    Clinical Background

    Autosomal dominant polycystic kidney disease (ADPKD) is an inherited disorder characterized by progressive renal cyst growth, enlargement of the kidneys, and progressive decline in kidney function that can lead to end‑stage renal disease. Tolvaptan is indicated to slow kidney function decline in adults with ADPKD who are at risk of rapidly progressing disease.

    Definitions and Key Terms

    inv-18: Rapidly progressing ADPKD
    Historical eGFR declineHistorical eGFR decline ≥ 3.0 mL/min/1.73 m2 is an example of rapid progression
    Mayo classificationsMayo Classification 1C–1E (1C requires case‑by‑case evaluation) indicate rapid progression
    Guideline referencesExamples derived from European and KDIGO guidance cited in policy
    inv-19: Baseline eGFR
    Baseline measurement timingeGFR measured prior to treatment with any tolvaptan product
    Minimum valueBaseline eGFR must be ≥ 25 mL/min/1.73 m2 for approval
    Documentation requirement
    Policy Summary
    PayerCigna
    PolicyTolvaptan (Jynarque)
    Policy CodePolicy IP0287
    Change TypeMaterial revision — clarified baseline eGFR and added renal replacement therapy prohibition
    Effective DateAug 1, 2026
    Last ReviewAug 1, 2026
    Next Review DateN/A
    Key ActionObtain prior authorization and document baseline eGFR ≥ 25 mL/min/1.73 m2 and that the patient is not on dialysis or has had a transplant.
    SourceLink
    On This Page
    Coverage Criteria for Tolvaptan (Jynarque and Generic)Key Clinical Thresholds and Coding-related MetricsPrior Authorization, Documentation, and Provider RequirementsClinical BackgroundDefinitions and Key Terms
    Use in evaluation
    May be used as supporting documentation that disease is rapidly progressing
    inv-08: eGFR threshold
    eGFR thresholdEstimated glomerular filtration rate (eGFR) ≥ 25 mL/min/1.73 m2
    Baseline timingRequirement applies to baseline measurement prior to any tolvaptan treatment
    Policy effectFailure to document baseline eGFR ≥ 25 mL/min/1.73 m2 may result in denial
  1. Patient must not be on renal replacement therapy (defined as dialysis or kidney transplantation).
  2. Step Therapy

    Employer plans: trial of bioequivalent generic required before brand

    For Employer Plans, the patient must have tried the bioequivalent generic tolvaptan tablets before brand Jynarque unless the patient cannot take the generic due to a formulation difference in inactive ingredient(s) that would cause, per the prescriber, a significant allergy or serious adverse reaction.

    • Trial of bioequivalent generic required before brand for Employer Plans.
    • Exemption allowed if inactive ingredient difference causes significant allergy or serious adverse reaction (per prescriber).
    Note

    Preferred product reference — Employer Plans Preferred Product table (generic availability)

    See Employer Plans Preferred Product table referenced in the revision details; Jynarque tablets are now available as a generic product and the preferred product table applies (no criteria changes to Jynarque tablets or therapy pack).

    • Jynarque tablets are now available as a generic product.
    • Employer Plans Preferred Product table referenced for preferred product rules; no criteria changes for tablets or therapy pack.
    Documentation Required

    Required clinical documentation: age, rapidly progressing ADPKD, baseline eGFR, and specialist involvement

    Prescriber documentation must show the patient is ≥ 18 years of age, that the patient has rapidly progressing ADPKD (as stated by the prescriber), the baseline eGFR value (≥ 25 mL/min/1.73 m2), and that the patient is not on renal replacement therapy; the medication must be prescribed by or in consultation with a nephrologist.

    • Age ≥ 18 documented.
    • Prescriber statement of rapidly progressing ADPKD (examples include eGFR decline ≥ 3.0 mL/min/1.73 m2 or Mayo Classification 1C–1E).
    • Baseline eGFR value documented (≥ 25 mL/min/1.73 m2).
    • Documentation that patient is not on renal replacement therapy (dialysis or transplant).
    • Medication prescribed by or in consultation with a nephrologist.
    Documentation Required

    Baseline eGFR documentation required (eGFR ≥ 25 mL/min/1.73 m2 prior to any tolvaptan)

    Baseline eGFR documentation is required to show an eGFR ≥ 25 mL/min/1.73 m2 prior to treatment with any tolvaptan product; baseline is defined as prior to any tolvaptan therapy and documentation that the patient is not on renal replacement therapy is also required.

    • Baseline defined as prior to treatment with any tolvaptan product.
    • Required baseline threshold: eGFR ≥ 25 mL/min/1.73 m2.
    • Document absence of renal replacement therapy (dialysis or transplantation).
    Denial Risk

    Denial risk if no prior authorization or for non-ADPKD indications (including hyponatremia)

    Requests submitted without prior authorization or requests for uses other than ADPKD (including hyponatremia) will be denied as not medically necessary.

    • Tolvaptan for non-ADPKD indications (e.g., hyponatremia) is considered not medically necessary under this policy.
    • Concomitant use with Samsca (other tolvaptan product for hyponatremia) is not recommended.
    Denial Risk

    Denial triggers: baseline eGFR < 25 or patient on renal replacement therapy

    Requests may be denied if the patient’s baseline eGFR is < 25 mL/min/1.73 m2 or if the patient is on renal replacement therapy (dialysis or kidney transplantation).

    • Denial trigger: baseline eGFR less than 25 mL/min/1.73 m2.
    • Denial trigger: patient on renal replacement therapy (dialysis or transplantation).
    Baseline eGFR must be documented in prior authorization materials
    inv-20: Renal replacement therapy
    DefinitionRenal replacement therapy is defined as dialysis or kidney transplantation
    Coverage effectPatients on renal replacement therapy are ineligible for tolvaptan under this policy
    DocumentationPA requests must state that the patient is not on renal replacement therapy
    inv-21: Baseline
    Baseline definedBaseline is defined as prior to treatment with any tolvaptan product
    Relation to eGFR requirementBaseline definition clarifies timing for the ≥ 25 mL/min/1.73 m2 eGFR requirement
    Policy changeClarified in revision details to replace previous Stage 5 CKD language
    inv-22: Renal replacement therapy
    Definition (duplicate)Renal replacement therapy = dialysis or kidney transplantation
    Exclusion effectPatients receiving dialysis or with a kidney transplant are excluded from tolvaptan therapy
    Added requirementPolicy explicitly added this prohibition in recent revisions